期刊文献+

西妥昔单抗联合适形调强放疗对局部晚期鼻咽癌的临床疗效分析 被引量:4

Clinical analysis of cetuximab combined with intensity modulated radiation therapy in treatment of local re- gionally advanced nasopharyngeal carcinoma
原文传递
导出
摘要 目的 探讨西妥昔单抗联合适形调强放疗对局部晚期鼻咽癌的临床疗效和安全性.方法 58例初治鼻咽癌患者随机分为治疗组和对照组.对照组采用适形调强放疗治疗,治疗组采用西妥昔单抗联合适形调强放疗治疗.评价近期疗效,观察毒副反应,随访1年评价客观疗效.结果 治疗结束时和治疗后3个月,治疗组鼻咽和颈部淋巴结完全缓解率均显著高于对照组(P<0.05);随访率100%,中位随访时间12个月,两组患者在随访期内无死亡;治疗组局部控制率为89.3%,显著高于对照组(73.3%)(x2 =4.135,P<0.05);治疗组远处转移率为3.6%,显著低于对照组(23.3%)(x2 =5.713,P<0.05);两组大部分急性毒性反应均在1~2度,且差异无统计学意义(P>0.05);治疗组28例患者治疗期间均出现座疮样皮疹,经过对症处理和营养支持治疗后恢复.结论 西妥昔单抗联合适形调强放疗对局部晚期鼻咽癌临床疗效肯定,毒副反应小,值得临床推广. Objective To evaluate the efficacy and toxicity in local regionally advanced nasopharyngeal carcinoma(NPC) patients treated by cetuximab combined with intensity modulated radiation therapy.Methods 58 cases of untreated NPC patients were randomly divided into treatment group and control group.The treatment group was given the treatment of cetuximab combined with intensity modulated radiation therapy,the control group was given the treatment of intensity modulated radiation therapy.The short-term efficacy and toxicity were evaluated,followed up for 1-year the objective response was evaluated.Results After treatment and 3 months after treatment,the CR rate of the nasopharynx and cervical lymph node of the treatment group were higher than the control group,compared with control group the difference was significant(P 〈0.05) ;Follow-up rate was 100%,the median follow-up time was 12 months,all patients were no deaths in the follow-up period; the local control rate of the treatment group was 89.3%,it was higher than the control group(73.3% ),compared with control group the difference was significant( P 〈0.05) ;The distant metastasis rate of the treatment group was 3.6%,it was lower than the control group(23.3 % ),compared with control group the difference was significant( P 〈0.05) ;Most acute toxicity of the two groups were 1 to 2 degrees,and the difference was not statistically significant( P 〉 0.05 ) ; During the treatment,28 patients of the treatment group occurred acne-like rash,after symptomatic treatment and nutritional support therapy was initiated.Conclusion The cetuximab combined with intensity modulated radiation therapy in treatment of local regionally advanced nasopharyngeal carcinoma had better efficacy and lower toxicity,the therapy method was worthy to be popularized.
出处 《中国基层医药》 CAS 2011年第24期3323-3325,共3页 Chinese Journal of Primary Medicine and Pharmacy
基金 广东省中山市2011年度科技计划项目(20113A141)
关键词 鼻咽肿瘤 西妥昔 放射疗法 适形 Nasopharyngeal neoplasms Cetuximab Radiation therapy, modulated
  • 相关文献

参考文献19

二级参考文献127

共引文献131

同被引文献20

  • 1王树森,管忠震,向燕群,汪波,林桐榆,姜文奇,张力,张惠忠,侯景辉.鼻咽癌组织中EGFR和p-ERK蛋白表达的检测及意义[J].中华肿瘤杂志,2006,28(1):28-31. 被引量:46
  • 2黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 3吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 4Modjtahedi H,Essapen S. Epidermal growth factor receptorinhibitors in cancer treatment: advances, challenges andopportunities[J].Anticancer Drugs, 2009, 20(10): 851-855.
  • 5Jadad AR,Moore RA, Carroll D, et al. Assessing the qualityof reports of randomized clinical trials: is blinding necessary.. Control Clin Trials, 1996, 17(1): 1-12.
  • 6Moher D, Pham B, Jones A,et al. Does quality of reports ofrandomised trials affect estimates of intervention efficacyreported in meta-anaIyses.[J]. Lancet, 1998,352(9128):609-613.
  • 7Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody [J]. Semin Oncol,2002,29(5 Suppl 14): 55-60.
  • 8Milas L, Mason K, Hunter N, et al. In vivo enhancement oftumor radioresponse by C225 antiepidermal growth factorreceptor antibody[J]. Clin Cancer Res, 2000,6(2): 701-708.
  • 9Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual [ M]. 7th edition. New York: Springer, 2009:103 - 115.
  • 10林榕波,郭增清,陈奕贵,范南峰,王晓杰,陈帆,刘捷,林锦源.西妥昔单抗联合伊立替康治疗化疗耐药晚期结直肠癌[J].中国癌症杂志,2008,18(1):79-80. 被引量:19

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部